FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1146-1148 October 26, 1995 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Hepatitis B virus (HBV) infection has a major impact on the public health because of its frequency, morbidity, and late consequences. In the United States about 200,000 primary HBV infections occur annually. Between 5 and 10 percent of patients with primary infection become chronically infected. There are probably 750,000 to 1 million HBV carriers in the United States, and worldwide the number of carriers is 200 million to 300 million. Each year in the United States as many as 5000 patients die of chronic HBV infection (about 4000 from cirrhosis and 600 to 1000 from complicating liver cancer).¹ Hence, considerable . . . [Full Text of this Article]

References

Related Letters:

Severe Toxicity of Fialuridine (FIAU)
Bari A., Josephson L., Prince A. M., Lewis W., Perrino F. W., Gordon M., Hoofnagle J., McKenzie R., Straus S., Swartz M. N., Stotka J. L.
Extract | Full Text  
N Engl J Med 1996; 334:1135-1138, Apr 25, 1996. Correspondence

This article has been cited by other articles:

• Bari, A., Josephson, L., Prince, A. M., Lewis, W., Perrino, F. W., Gordon, M., Hoofnagle, J., McKenzie, R., Straus, S., Swartz, M. N., Stotka, J. L. (1996). Severe Toxicity of Fialuridine (FIAU). NEJM 334: 1135-1138 [Full Text]